ENDRA Life Sciences (NASDAQ: NDRA) is one of 48 publicly-traded companies in the “Electromedical equipment” industry, but how does it weigh in compared to its competitors? We will compare ENDRA Life Sciences to related businesses based on the strength of its valuation, institutional ownership, analyst recommendations, risk, earnings, profitability and dividends.
Insider and Institutional Ownership
17.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 44.0% of shares of all “Electromedical equipment” companies are owned by institutional investors. 11.4% of ENDRA Life Sciences shares are owned by company insiders. Comparatively, 15.9% of shares of all “Electromedical equipment” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
ENDRA Life Sciences has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences’ competitors have a beta of 1.60, indicating that their average stock price is 60% more volatile than the S&P 500.
This table compares ENDRA Life Sciences and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|ENDRA Life Sciences||N/A||-326.97%||-233.06%|
|ENDRA Life Sciences Competitors||-286.93%||-140.79%||-18.41%|
Valuation and Earnings
This table compares ENDRA Life Sciences and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|ENDRA Life Sciences||$10,000.00||-$9.80 million||-0.72|
|ENDRA Life Sciences Competitors||$1.21 billion||$130.86 million||14.25|
ENDRA Life Sciences’ competitors have higher revenue and earnings than ENDRA Life Sciences. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current ratings and recommmendations for ENDRA Life Sciences and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|ENDRA Life Sciences||0||0||3||0||3.00|
|ENDRA Life Sciences Competitors||253||689||1296||62||2.51|
ENDRA Life Sciences presently has a consensus price target of $6.00, suggesting a potential upside of 297.35%. As a group, “Electromedical equipment” companies have a potential upside of 21.65%. Given ENDRA Life Sciences’ stronger consensus rating and higher possible upside, equities research analysts clearly believe ENDRA Life Sciences is more favorable than its competitors.
ENDRA Life Sciences competitors beat ENDRA Life Sciences on 9 of the 13 factors compared.
ENDRA Life Sciences Company Profile
ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.